Multi-Year Agreement Enables Global CRO toOffer Phase Forward`s InForm EDC
Solution to PharmaNet Customers Worldwide
WALTHAM, Mass.--(Business Wire)--
Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions
for clinical trials and drug safety, today announced a multi-year agreement with
PharmaNet Development Group, Inc., a global drug development services company,
that enables PharmaNet to offer Phase Forward`s InForm electronic data capture
(EDC) solution to PharmaNet customers worldwide. PharmaNet provides a
comprehensive range of services to the pharmaceutical, biotechnology, generic
drug and medical device industries that includes clinical trial data management.
"We chose to team with Phase Forward on the basis of our successful
collaboration on behalf of several pharmaceutical companies," said Thomas
Newman, M.D., President, PharmaNet Late Stage Development. "That experience
indicated the complementary nature of Phase Forward`s established leadership in
EDC technology solutions and our expertise in providing clinical trial services
to a broad range of industries. We look forward to extending to other customers
the success our work together has already achieved."
"Customers are turning to PharmaNet for its proven expertise in providing the
critical services infrastructure required to optimize the clinical trial
process," said Steve Powell, senior vice president, Phase Forward. "Our InForm
EDC solution is a perfect addition to PharmaNet`s expertise and we look forward
to building on and expanding our work together."
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company,
provides a comprehensive range of services to the pharmaceutical, biotechnology,
generic drug and medical device industries. The Company offers early and late
stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase
II, III and IV clinical development programs. With approximately 2,300 employees
and 40 facilities throughout the world, PharmaNet is a recognized leader in
outsourced clinical development. For more information, please visit our website
at www.pharmanet.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for
clinical trials and drug safety. Phase Forward`s products and services have been
utilized in over 10,000 clinical trials involving more than 1,000,000 clinical
trial study participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer
Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline,
Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk,
PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis,
Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines
and Healthcare Products Regulatory Agency. Additional information about Phase
Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based on historical
information are forward-looking statements which are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. This
press release contains express or implied forward-looking statements relating
to, among other things, the performance and features of Phase Forward`s products
and services, demand for Phase Forward`s products and services, future business
and operations plans of a Phase Forward customer, and the ability of Phase
Forward`s customers to realize benefits from the use of Phase Forward`s products
and services. These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond Phase
Forward's control, which could cause actual results to differ materially from
those contemplated in these forward-looking statements. In particular, the risks
and uncertainties include, among other things, the ability of Phase Forward`s
customers to realize benefits from the use of its products and services, the
possibility that customers` needs or plans may change over time, the possibility
that the level of demand for Phase Forward`s products and services may vary,
regulatory changes and competition. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release, whether as a
result of new information, future events or circumstances or otherwise. For
additional disclosure regarding these and other risks faced by Phase Forward,
see the disclosure contained in Phase Forward's public filings with the
Securities and Exchange Commission including, without limitation, its most
recent Annual Report on Form 10-K.
Phase Forward
Elaine Maynard, 781-902-4371
elaine.maynard@phaseforward.com
or
CHEN PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com
Copyright Business Wire 2009
